Neutrophils but not eosinophils are involved in growth suppression of IL-4-secreting tumors

Journal of Immunology

Volumn 160, Issue 1, 1998, Pages 345-350

  Noffz, Gabriele ^a   Qin, Zhihai ^a   Kopf, Manfred ^b   Blankenstein, Thomas ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b BASEL INSTITUTE FOR IMMUNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; EOSINOPHIL; EOSINOPHILIA; FIBROSARCOMA; GRANULOCYTE; MELANOMA B16; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, SURFACE; CHEMOKINES; EOSINOPHILS; FLOW CYTOMETRY; IMMUNITY, CELLULAR; INTERLEUKIN-4; INTERLEUKIN-5; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; SARCOMA, EXPERIMENTAL;

EID: 0031930938     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Blankenstein, T., S. Cayeux, and Z. Qin. 1996. Genetic approaches to cancer immunotherapy. Rev. Physiol. Biochem. Pharmacol. 129:1.
2. Golumbek, P. T., A. J. Lazenby, H. I. Levitsky, L. M. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
3. Hock, H., M. Dorsch, U. Kunzendorf, Z. Qin, T. Diamantstein, and T. Blankenstein. 1993. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc. Natl. Acad. Sci. USA 90:2774.
4. Tepper, R. I., P. K. Pattengale, and P. Leder. 1989. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503.
5. Tepper, R. I., R. L. Coffman, and P. Leder. 1992. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 257:548.
6. Wardlaw, A. J., R. Moqbel, and A. B. Kay. 1995. Eosinophils: biology and role in disease. Adv. Immunol. 60:151.
7. Desreumaux, P., and M. Capron. 1996. Eosinophils in allergic reactions. Curr. Opin. Immunol. 8:790.
8. Krüger-Krasagakes, S., W. Li, G. Richter, T. Diamantstein, and T. Blankenstein. 1993. Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth. Eur. J. Immunol. 23:992.
9. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol. 153:5659.
10. Takatsu, K., S. Takaki, and Y. Hitoshi. 1994. Interleukin-5 and its receptor system: implications in the immune system and inflammation. Adv. Immunol. 57: 145.
11. + B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 4:15.
12. Foster, P. S., S. P. Hogan, A. J. Ramsay, K. I. Matthaei, and I. G. Young. 1996. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183:195.
13. Yoshida, T., K. Ikuta, H. Sugaya, K. Maki, M. Takagi, H. Kanazawa, S. Sunaga, T. Kinashi, K. Yoshimura, J. Miyazaki, S. Takaki, and K. Takatsu. 1996. Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity 4:483.
14. Fidler, I. J. 1973. Selection of successive tumour lines for metastasis. Nat. New Biol. 242:148.
15. Karp, S. E., A. Farber, J. C. Salo, P. Hwu, G. Jaffe, A. L. Asher, E. Shiloni, N. P. Restifo, J. J. Mule, and S. A. Rosenberg. 1993. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: tumor inhibition by IL-2 but not tumor necrosis factor. J. Immunol. 150:896.
16. Blankenstein, T., E. Winter, and W. Muller. 1988. A retroviral expression vector containing murine immunoglobulin heavy chain promoter/enhancer. Nucleic Acids Res. 16:10939.
17. Lupton, S. D., L. L. Brunton, V. A. Kalberg, and R. W. Overell. 1991. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol. Cell. Biol. 11:3374.
18. Cayeux, S., B. Dörken, and T. Blankenstein. 1997. Tumor cell vaccines using genetically modified cells coexpressing cytokines and the T cell costimulatory molecule B7. In Concepts in Gene Therapy. M. Strauss and J. Barranger, eds. Walter de Gruyter, Berlin, p. 485.
19. Miller, A. D., and C. Buttimore. 1986. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6: 2895.
20. Mann, R., R. C. Mulligan, and D. Baltimore. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33:153.
21. Hu, L. J., J. Ohara, C. Watson, W. Tsang, and W. E. Paul. 1989. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J. Immunol. 142:800.
22. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55.
23. Rolink, A. G., F. Melchers, and R. Palacios. 1989. Monoclonal antibodies reactive with the mouse interleukin 5 receptor. J. Exp. Med. 169:1693.
24. Watt, S. M., A. W. Burgess, and D. Metcalf. 1979. Isolation and surface labeling of murine polymorphonuclear neutrophils. J. Cell. Physiol. 100:1.
25. Yukawa, T., C. Kroegel, P. Evans, T. Fukuda, K. F. Chung, and P. J. Barnes. 1989. Density heterogeneity of eosinophil leukocytes: induction of hypodense eosinophils by platelet-activating factor. Immunology 68:140.
26. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
27. Mould, A. W., K. I. Matthaei, I. G. Young, and P. R. A. Foster. 1997. Relationship between interleukin 5 and eotaxin in regulating blood and tissue eosinophilia in mice. J. Clin. Invest. 99:1064.
28. Rothenberg, M. E., A. D. Luster, and P. Leder. 1995. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4 induced tumor suppression. Proc. Natl. Acad. Sci. USA 92:8960.
29. Hestdal, K., F. W. Ruscetti, J. N. Ihle, S. E. Jacobsen, C. M. Dubois, W. C. Kopp, D. L. Longo, and J. R. Keller. 1991. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 147:22.
30. Platzer, C., G. Richter, K. Überla, H. Hock, T. Diamantstein, and T. Blankenstein. 1992. Interleukin-4-mediated tumor suppression in nude mice involves interferon-gamma. Eur. J. Immunol. 22:1729.
31. Pericle, F., R. A. Kirken, B. P. Epling, D. K. Blanchard, and J. Y. Djeu. 1996. Direct killing of interleukin-2-transfected tumor cells by human neutrophils. Int. J. Cancer 66:367.
32. Musiani, P., A. Allione, A. Modica, P. L. Lollini, M. Giovarelli, F. Cavallo, F. Belardelli, G. Forni, and A. Modesti. 1996. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab. Invest. 74:146.
33. Colombo, M. P., L. Lombardi, A. Stoppacciaro, C. Melani, M. Parenza, B. Bottazzi, and G. Parmiani. 1992. Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo: neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing rumor cells. J. Immunol. 149:113.
34. Finkelman, F. D., E. J. Pearce, J. J. Urban, and A. Sher. 1991. Regulation and biological function of helminth-induced cytokine responses. Immunol. Today 12:A-62.